ArticleNature communications2021
Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.
- Non-pharmaceutical interventions for COVID-19 reduced the incidence of infectious diseases: a controlled interrupted time-series study.Infectious diseases of poverty · 2023Pooled it
- Article
- The role of school terms in the epidemics of scarlet fever among pre-school-aged and school-aged children: a 15-year population-based surveillance in China.BMC public health · 2026Article
- Epidemiological characteristics and spatiotemporal analysis of hand-foot-mouth disease in Shandong Province, China.International health · 2026Article
- Incidence, risk factors and viral aetiology of lower respiratory infections among older adults: a 5-year multicentric cohort study in India.BMJ open respiratory research · 2026Observational
- The impact of COVID-19 non-pharmaceutical interventions on notifiable infectious diseases in Poland: a comprehensive analysis from 2014-2022.BMC infectious diseases · 2026Article
- Environmental surveillance reveals enterovirus diversity in Jinan, China: detection of types D68, A71, A76, B88, A90, and C99.Microbiology spectrum · 2026Article
- Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).The Journal of general virology · 2026Article
- Dynamic changes of hand, foot, and mouth disease epidemic crossing three periods in Jiangxi Province, China: a long-term epidemiology retrospective study from 2009 to 2022.BMC infectious diseases · 2026Article
- Incidence of community-acquired pneumonia among adults between 2016 and 2023: an observational cohort study.Epidemiology and infection · 2026Observational
- Effectiveness of a comprehensive nursing prevention and control system for respiratory infections in fever clinics in the era of co-existence of multiple pathogens.Frontiers in public health · 2026Article
- Epidemiological characteristics of childhood infectious diseases at Qingyang maternal and child health care hospital during the COVID-19 pandemic and the post-pandemic period.Frontiers in pediatrics · 2026Article
- Article
- Impact of meteorological factors on the incidence of hand, foot, and mouth disease caused by major enterovirus pathogens: a distributed lag nonlinear analysis in Fujian Province, China.BMC infectious diseases · 2025Article
- Spatio-temporal patterns and associated factors of influenza-like illness outbreaks in Chinese mainland: a Bayesian modeling study.BMC public health · 2025Article
- The epidemiological characteristics of notifiable infectious diseases in a Yunnan hospital, China, 2014-2023.BMC public health · 2025Article
- Elevated risk of infectious diseases in adulthood after prenatal or early postnatal exposure to the Great Chinese Famine.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Epidemiological analysis of infectious diseases in older people in China from 2014 to 2022: a population-based study.The Lancet regional health. Western Pacific · 2025Article
- A "Pandemic-Proof" Methodology for Outbreak Detection Adapted From COVID-19's Impact on Notifications of Infectious Diseases in the Netherlands: Surveillance Study.JMIR public health and surveillance · 2025Article
- Epidemiological Characteristics and Influencing Factors of Bacillary Dysentery Outbreaks - China, 2008-2024.China CDC weekly · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
Nationwide nonpharmaceutical interventions (NPIs) have been effective at mitigating the spread of the novel coronavirus disease (COVID-19), but their broad impact on other diseases remains under-investigated. Here we report an ecological analysis comparing the incidence of 31 major notifiable infectious diseases in China in 2020 to the average level during 2014-2019, controlling for temporal phases defined by NPI intensity levels. Respiratory diseases and gastrointestinal or enteroviral diseases declined more than sexually transmitted or bloodborne diseases and vector-borne or zoonotic diseases. Early pandemic phases with more stringent NPIs were associated with greater reductions in disease incidence. Non-respiratory diseases, such as hand, foot and mouth disease, rebounded substantially towards the end of the year 2020 as the NPIs were relaxed. Statistical modeling analyses confirm that strong NPIs were associated with a broad mitigation effect on communicable diseases, but resurgence of non-respiratory diseases should be expected when the NPIs, especially restrictions of human movement and gathering, become less stringent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.